Breakthrough medicines to improve gastrointestinal function

Motus is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases. Motus’ lead product candidate, relamorelin, is a potent, best-in-class, Phase 2 ghrelin agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes and other GI functional disorders for which there are currently limited therapeutic options.

Motus spun out of Rhythm Health in 2016 and was acquired by Allergan later the same year.

Year Invested: 2010
Location: Boston, Mass.

Recent News

October 27, 2016
Allergan to Acquire GI Disease Subsidiary of Rhythm Holding Company, LLC, Expanding Innovative Gastroenterology Pipeline

April 4, 2016
Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis

April 4, 2016
Motus Presents Clinical Proof-of-Concept Results for Relamorelin in the Treatment of Anorexia

Read More News

Associated Team Members

Neil Exter